Table 2.
Outcome of 30-day all-cause mortality
| Univariate | Multivariate | |||||
|---|---|---|---|---|---|---|
| No. of patients | No. of events | HR(95%CI) | P value | aHR(95%CI) | P value | |
| TA | ||||||
| High dose | 86 | 24 | 1.340 (0.820,2.570) | 0.201 | 1.464 (0.829,2.584) | 0.189Ú |
| Standard dose | 158 | 32 | 1 | reference | 1 | reference |
| TAE | ||||||
| High dose | 60 | 16 | 1.640 (0.798,3.360) | 0.179 | 1.730 (0.756, 3.959) | 0.195† |
| Standard dose | 115 | 19 | 1 | reference | 1 | reference |
| Targeted TAE | ||||||
| High dose | 58 | 15 | 1.540 (0.700, 3.380) | 0.284 | 1.347 (0.651, 2.789) | 0.423‡ |
| Standard dose | 102 | 19 | 1 | reference | 1 | reference |
Ú: For multivariate analysis, the adjusting factors included age, medicine history, chronic kidney diseases, gastrointestinal cancer, cardiac diseases, endoscopy, GBS and SI.
†: For multivariate analysis, the adjusting factors included liver diseases, gastrointestinal cancer, cardiac diseases, endoscopy, GBS and SI.
‡: For multivariate analysis, the adjusting factors included gastrointestinal cancer, cardiac diseases, endoscopy, GBS and SI.
TA, Transcatheter angiography; TAE, transcatheter arterial embolization; CI, confidence interval; HR, hazard ratio; aHR, adjusted hazard ratio